Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Nonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisType 2 Diabetes
Interventions
DRUG

Liraglutide-metformin vs insulin-metformin

"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."

Trial Locations (1)

H2W 1T7

Centre hospitalier de l'Université de Montréal, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

OTHER

collaborator

Diabetes Québec

OTHER

collaborator

Radiological Society of North America

OTHER

collaborator

Canadian Heads of Academic Radiology-GE Healthcare Development Award

UNKNOWN

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter